Colorectal Cancer | Specialty

EPOC Studies: Preoperative Treatments in CRC

September 29th 2013

PRIME Trial: RAS Mutations in Metastatic Colorectal Cancer

September 29th 2013

TRIBE Trial: First-Line Treatment of mCRC

September 29th 2013

Dr. Mitchell on Survival and Safety of the VELOUR Trial

September 23rd 2013

Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, discusses an analysis of the VELOUR trial.

Merrimack's GI Cancer Agents Show Promise

September 20th 2013

Merrimack Pharmaceuticals is combining biology, computing, and engineering in order to gain a comprehensive understanding of the dynamics of different types of cancer and then use that information to develop new therapeutics.

Dr. Eckhardt on the Wnt Pathway in Colorectal Cancer

September 18th 2013

S. Gail Eckhardt, MD, professor and head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the wnt pathway and its role in colorectal cancer.

First Generic Version of Capecitabine Gains FDA Approval

September 16th 2013

The FDA has approved the first generic formulation of capecitabine, an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer and metastatic breast cancer.

Dr. Mitchell on Colorectal Cancer Treatment Options

September 10th 2013

Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, talks about the growing number of drugs and regimens for patients with colorectal cancer.

Dr. Eckhardt on Angiogenesis Inhibition in Metastatic CRC

August 20th 2013

Gail Eckhardt, MD, from the University of Colorado Denver and Health Sciences Center, discusses the future role of aflibercept for patients with metastatic colorectal cancer.

New Phase III Trial

August 19th 2013

PACES trial will evaluate 2 drugs to prevent colon adenomas.

Dr. Lenz Describes Excitement Over Advances in GI Cancer

August 16th 2013

Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, believes this is an exciting time in the field of gastrointestinal cancers, as more tools become available to select the most effective treatment for each patient.

RAS Mutation Status Key to Panitumumab Use in mCRC

July 30th 2013

The presence or absence of RAS mutations should dictate use of panitumumab in combination with FOLFOX chemotherapy for patients with metastatic colorectal cancer.

Dr. Kaufman on the Importance of the Immunoscore

July 16th 2013

Howard L. Kaufman, MD, Rush University Medical Center, discusses the implications of the Immunoscore for the treatment of patients with cancer.

Dr. Marc Peeters on the Aflibercept Toxicity Profile

July 9th 2013

Marc Peeters, MD, PhD, from the Antwerp University Hospital, discusses the importance of properly managing the toxicities associated with aflibercept when treating patients with metastatic colorectal cancer.

IV Calcium/Magnesium Has No Effect on Oxaliplatin-Induced Neuropathy

July 6th 2013

Intravenous calcium plus magnesium given before or after adjuvant FOLFOX chemotherapy has absolutely no effect on the development of sensory neurotoxicity induced by oxaliplatin.

Dr. Lenz Explores KRAS/NRAS Mutations in Colorectal Cancer

July 6th 2013

Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, discusses the potential predictive impact of KRAS and NRAS mutations in metastatic colorectal cancer.

Simple, Inexpensive Blood Test Poised to Be a Real "Game Changer" in CRC Screening

July 6th 2013

A simple and inexpensive blood test is being developed that can be used to screen patients for premalignant colorectal cancer lesions which, once perfected, will be a real game changer.

Better Responders in VELOUR Derive Enhanced Benefit From Aflibercept

July 6th 2013

Better responders within a cohort of patients from the VELOUR study derive enhanced benefit from aflibercept when combined with FOLFIRI, a post-hoc analysis of the study shows.

Dr. Ruff on Selecting Anti- Angiogenic Agents in mCRC

July 5th 2013

Paul Ruff, MD, from the University of Witwatersrand, Johannesburg, South Africa, elaborates on factors that can be utilized to select an appropriate antiangiogenic therapy as a second-line treatment in metastatic colorectal cancer.

Dr. Mitchell on a Subgroup Analysis of the VELOUR Trial

June 26th 2013

Edith Mitchell, MD, FACP, from Thomas Jefferson University, gives an overview of the North American subgroup analysis of the VELOUR trial.